<DOC>
	<DOCNO>NCT02991612</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Rifaximin treatment cirrhotic gastroesophageal variceal bleeding .</brief_summary>
	<brief_title>Rifaximin Patients With Gastroesophageal Variceal Bleeding</brief_title>
	<detailed_description>Gastroesophageal variceal bleed common life-threatening condition patient portal hypertension , susceptibility bacterial infection . However , prophylaxis use antibiotic remain uncertain lack high level evidence .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Gastrointestinal Hemorrhage</mesh_term>
	<mesh_term>Esophageal Gastric Varices</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>18 y.o . ≤age≤75 y.o . ; Cirrhotic gastroesophageal variceal bleed underwent endoscopic treatment ( include esophageal varix ligation , endoscopic injection sclerosis gastric N butylcyanoacrylate injection ) . age &lt; 18 y.o . age &gt; 75 y.o . ; Never variceal bleed episode ; Do endoscopic treatment ; combine malignant tumor ( exclude patient hepatocellular carcinoma n't need treatment moment ) ; Known infection endoscopic treatment ( Fever , microbial culture positive , et al . ) Massive ascites combine high risk factor require prophylaxis use antibiotic . Acute variceal bleed within 5 day . Use antibiotic past 2 week ; Refuse participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>